Acknowledgement
Health and Medical Research Fund, Hong Kong (No. 03143616 and 06171706) supported this project. Dr. Elaine YP Lee is the primary investigator for these funds.
References
- Webb PM, Jordan SJ. Epidemiology of epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol 2017;41:3-14 https://doi.org/10.1016/j.bpobgyn.2016.08.006
- Narod S. Can advanced-stage ovarian cancer be cured? Nat Rev Clin Oncol 2016;13:255-261 https://doi.org/10.1038/nrclinonc.2015.224
- Hoppenot C, Eckert MA, Tienda SM, Lengyel E. Who are the long-term survivors of high grade serous ovarian cancer? Gynecol Oncol 2018;148:204-212 https://doi.org/10.1016/j.ygyno.2017.10.032
- du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials. Cancer 2009;115:1234-1244 https://doi.org/10.1002/cncr.24149
- Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002;20:1248-1259 https://doi.org/10.1200/JCO.2002.20.5.1248
- Aletti GD, Dowdy SC, Gostout BS, Jones MB, Stanhope CR, Wilson TO, et al. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstet Gynecol 2006;107:77-85 https://doi.org/10.1097/01.AOG.0000192407.04428.bb
- Wimberger P, Lehmann N, Kimmig R, Burges A, Meier W, Du Bois A; Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group. Prognostic factors for complete debulking in advanced ovarian cancer and its impact on survival. An exploratory analysis of a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR). Gynecol Oncol 2007;106:69-74 https://doi.org/10.1016/j.ygyno.2007.02.026
- Querleu D, Planchamp F, Chiva L, Fotopoulou C, Barton D, Cibula D, et al. European Society of Gynaecological Oncology (ESGO) guidelines for ovarian cancer surgery. Int J Gynecol Cancer 2017;27:1534-1542 https://doi.org/10.1097/IGC.0000000000001041
- Fagotti A, Ferrandina G, Fanfani F, Ercoli A, Lorusso D, Rossi M, et al. A laparoscopy-based score to predict surgical outcome in patients with advanced ovarian carcinoma: a pilot study. Ann Surg Oncol 2006;13:1156-1161 https://doi.org/10.1245/ASO.2006.08.021
- Pedro Antonio CC, Alvaro Jesus GR, Jose G, Elena G, Alida G, Francisco ML, et al. Validation of a peritoneal surface disease severity score in stage IIIC-IV ovarian cancer treated with cytoreduction and hyperthermic intraperitoneal chemotherapy. Surg Oncol 2019;28:57-61 https://doi.org/10.1016/j.suronc.2018.11.005
- Michielsen K, Vergote I, Op de Beeck K, Amant F, Leunen K, Moerman P, et al. Whole-body MRI with diffusion-weighted sequence for staging of patients with suspected ovarian cancer: a clinical feasibility study in comparison to CT and FDG-PET/CT. Eur Radiol 2014;24:889-901 https://doi.org/10.1007/s00330-013-3083-8
- Low RN, Sebrechts CP, Barone RM, Muller W. Diffusion-weighted MRI of peritoneal tumors: comparison with conventional MRI and surgical and histopathologic findings--a feasibility study. AJR Am J Roentgenol 2009;193:461-470 https://doi.org/10.2214/AJR.08.1753
- Winfield JM, Wakefield JC, Dolling D, Hall M, Freeman S, Brenton JD, et al. Diffusion-weighted MRI in advanced epithelial ovarian cancer: apparent diffusion coefficient as a response marker. Radiology 2019;293:374-383 https://doi.org/10.1148/radiol.2019190545
- Sorensen SM, Schnack TH, Hogdall C. Impact of residual disease on overall survival in women with Federation of Gynecology and Obstetrics stage IIIB-IIIC vs stage IV epithelial ovarian cancer after primary surgery. Acta Obstet Gynecol Scand 2019;98:34-43 https://doi.org/10.1111/aogs.13453
- Lee EYP, An H, Perucho JAU, Chiu KWH, Hui ES, Chu MMY, et al. Functional tumour burden of peritoneal carcinomatosis derived from DWI could predict incomplete tumour debulking in advanced ovarian carcinoma. Eur Radiol 2020;30:5551-5559 https://doi.org/10.1007/s00330-020-06887-6
- Sugarbaker PH. Successful management of microscopic residual disease in large bowel cancer. Cancer Chemother Pharmacol 1999;43 Suppl:S15-S25 https://doi.org/10.1007/s002800051093
- Gong NJ, Wong CS, Chu YC, Guo H, Huang B, Chan Q. Increasing the accuracy of volume and ADC delineation for heterogeneous tumor on diffusion-weighted MRI: correlation with PET/CT. Int J Radiat Oncol Biol Phys 2013;87:407-413 https://doi.org/10.1016/j.ijrobp.2013.05.026
- Elzarkaa AA, Shaalan W, Elemam D, Mansour H, Melis M, Malik E, et al. Peritoneal cancer index as a predictor of survival in advanced stage serous epithelial ovarian cancer: a prospective study. J Gynecol Oncol 2018;29:e47
- Tentes AA, Tripsiannis G, Markakidis SK, Karanikiotis CN, Tzegas G, Georgiadis G, et al. Peritoneal cancer index: a prognostic indicator of survival in advanced ovarian cancer. Eur J Surg Oncol 2003;29:69-73 https://doi.org/10.1053/ejso.2002.1380
- Gasimli K, Braicu EI, Richter R, Chekerov R, Sehouli J. Prognostic and predictive value of the peritoneal cancer index in primary advanced epithelial ovarian cancer patients after complete cytoreductive surgery: study of tumor bank ovarian cancer. Ann Surg Oncol 2015;22:2729-2737 https://doi.org/10.1245/s10434-014-4329-7
- Llueca A, Escrig J. Prognostic value of peritoneal cancer index in primary advanced ovarian cancer. Eur J Surg Oncol 2018;44:163-169 https://doi.org/10.1016/j.ejso.2017.11.003
- Lindgren A, Anttila M, Rautiainen S, Arponen O, Kivela A, Makinen P, et al. Primary and metastatic ovarian cancer: characterization by 3.0T diffusion-weighted MRI. Eur Radiol 2017;27:4002-4012 https://doi.org/10.1007/s00330-017-4786-z
- Hynninen J, Lavonius M, Oksa S, Grenman S, Carpen O, Auranen A. Is perioperative visual estimation of intra-abdominal tumor spread reliable in ovarian cancer surgery after neoadjuvant chemotherapy? Gynecol Oncol 2013;128:229-232 https://doi.org/10.1016/j.ygyno.2012.11.007
- Vergote I, Trope CG, Amant F, Kristensen GB, Ehlen T, Johnson N, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med 2010;363:943-953 https://doi.org/10.1056/NEJMoa0908806